Evidence map›Paper›PMID 40658234›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

Cognitive impairment and risk of dementia in heart failure: the exuberating role of digoxin.

Hayder M Al-Kuraishy, Esraa H Fahad, Ghassan M Sulaiman, Hamdoon A Mohammed, Majid S Jabir, Ali I Al-Gareeb, Ali K Albuhadily

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hayder M Al-KuraishyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
Esraa H FahadDepartment of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq.
Ghassan M SulaimanDepartment Biotechnology, College of Applied Sciences, University of Technology, Baghdad, 10066, Iraq. ghassan.m.sulaiman@uotechnology.edu.iq.
Hamdoon A MohammedDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Qassim, 51452, Saudi Arabia.
Majid S JabirDepartment Biotechnology, College of Applied Sciences, University of Technology, Baghdad, 10066, Iraq.
Ali I Al-GareebJabir Ibn Hayyan Medical University, Kufa, Najaf, 54001, Iraq.
Ali K AlbuhadilyDepartment of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a clinical syndrome with a wide range of presentations due to functional and structural abnormalities of the heart. HF may induce the development of cognitive impairment and increased risk of dementia. HF frequently coexists with cognitive impairments in about 40-60% of elderly patients. In addition, cognitive impairment reduces life quality and increases mortality in patients with HF, signifying a close interrelated relationship between HF and cognitive impairment. Prominently, regional brain hypoperfusion in patients with HF leads to autonomic dysfunction, mood, and cognitive disorders. HF increases the risk of vascular dementia (VD), which refers to cardiogenic dementia. Remarkably, the anti-failure drug digoxin, which is commonly used in the management of HF, affects the development of cognitive impairment and dementia. Numerous studies highlighted the neuroprotective effect of digoxin against the development of cognitive impairment and dementia. Though, the fundamental neuroprotective mechanisms of digoxin against cognitive impairment and dementia are not completely explained. This review seeks to examine the relationship between heart failure and the onset of cognitive impairment and dementia, as well as the role of digoxin in mitigating the adverse impact of heart failure on cognitive function.

Indexed as

Cardiotonic AgentsCognitionCognitive DysfunctionDementiaDigoxinHeart FailureNeuroprotective AgentsAnimalsHumansRisk FactorsCardiotonic AgentsDigoxinNeuroprotective AgentsCognitive impairmentDementiaDigoxinHeart failurePathogenesis

Identifiers

PMID40658234

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.